Effects of the vasodilating beta-blocker nebivolol on smoking-induced endothelial dysfunction in young healthy volunteers

Vascular Health and Risk Management

Volumn 4, Issue 4, 2008, Pages 909-915

  Schmidt, André C ^a   Flick, Burkhard ^a   Jahn, Elke ^b   Bramlage, Peter ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Chemie AG   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

C reactive protein; Endothelial dysfunction; Nebivolol; Nitric oxide (NO); Smoking

Indexed keywords

C REACTIVE PROTEIN; NEBIVOLOL;

ADULT; ARTICLE; ASTHENIA; BLOOD CLOTTING; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; FATIGUE; FOREARM BLOOD FLOW; HUMAN; INFLUENZA; MALE; MORNING DOSAGE; MUSCLE CRAMP; NAUSEA; OPEN STUDY; PILOT STUDY; PLETHYSMOGRAPHY; PROTEIN BLOOD LEVEL; RHINOPHARYNGITIS; SORE THROAT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOLUNTEER;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; BENZOPYRANS; BLOOD COAGULATION; BLOOD PRESSURE; C-REACTIVE PROTEIN; ELECTROCARDIOGRAPHY; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; FOREARM; HEART RATE; HUMANS; INFLAMMATION MEDIATORS; MALE; PILOT PROJECTS; PLETHYSMOGRAPHY; REGIONAL BLOOD FLOW; SMOKING; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS; YOUNG ADULT;

EID: 52249121952     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ablij H, Meinders A. 2002. C-reactive protein: history and revival. Eur J Intern Med, 13:412.
2. Blake GJ, Ridker PM. 2002. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med, 252:283-94.
3. Brooders MA, Doevendans PA, Bekkers BC, et al. 2000. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta2-adrenergic receptor-mediated nitric oxide production. Circulation, 102:677-84.
4. Brunner H, Cockcroft JR, Deanfield J, et al. 2005. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens, 23:233-46.
5. Cai H, Harrison DG. 2000. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res, 87:840-4.
6. Celermajer DS, Sorensen KE, Georgakopoulos D, et al. 1993. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation, 88:2149-55.
7. Cockcroft J. 2004. Nebivolol: a review. Expert Opin Pharmacother, 5:893-9.
8. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. 1995. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/ NO-dependent mechanism. J Pharmacol Exp Ther, 274:1067-71.
9. Eagles CJ, Martin U. 1998. Non-pharmacological modification of cardiac risk factors: part 3. Smoking cessation and alcohol consumption. J Clin Pharm Ther, 23:1-9.
10. Esen AM, Barutcu I, Acar M, et al. 2004. Effect of smoking on endothelial function and wall thickness of brachial artery. Circ J, 68:1123-6.
11. Fichtlscherer S, Zeiher AM. 2000. Endothelial dysfunction in acute coronary syndromes: association with elevated C-reactive protein levels. Ann Med, 32:515-8.
12. Kao PC, Shiesh SC, Wu TJ. 2006. Serum C-reactive protein as a marker for wellness assessment. Ann Clin Lab Sci, 36:163-9.
13. Lekakis JP, Protogerou A, Papamichael C, et al. 2005. Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease. Cardiovasc Drugs Ther, 19:277-81.
14. Lind L, Sarabi M, Millgard J. 2003. The effect of smoking on endothelial vasodilatory function evaluated by local infusion of metacholine in the forearm is dependent on the duration of smoking. Nicotine Tob Res, 5:125-30.
15. Lu JT, Creager MA. 2004. The relationship of cigarette smoking to peripheral arterial disease. Rev Cardiovasc Med, 5:189-93.
16. Luscher TF, Noll G. 1996. Endothelial function as an end-point in interventional trials: concepts, methods and current data. J Hypertens Suppl, 14:S111-9; discussion S119-21.
17. Luscher TF, Spieker LE, Noll G, et al. 2001. Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors. J Cardiovasc Pharmacol, 38(Suppl 3):S3-11.
18. Marchesi S, Lupattelli G, Lombardini R, et al. 2005. Acute inflammatory state during influenza infection and endothelial function. Atherosclerosis, 178:345-50.
19. Moncada S, Higgs EA. 2006. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol, 147(Suppl 1):S193-201.
20. Roddie IC, Wallace WF. 1979. Methods for the assessment of the effects of drugs on the arterial system in man. Br J Clin Pharmacol, 7:317-23.
21. Sarabi M, Lind L. 2000. Short-term effects of smoking and nicotine chewing gum on endothelium-dependent vasodilation in young healthy habitual smokers. J Cardiovasc Pharmacol, 35:451-6.
22. Schmidt AC, Graf C, Brixius K, et al. 2007. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig, 27:841-9.
23. Verma S, Szmitko PE, Ridker PM. 2005. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med, 2:29-36; quiz 58.
24. Vyssoulis GP, Marinakis AG, Aznaouridis KA, et al. 2004. The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking. Am J Hypertens, 17:582-9.
25. Whitney RJ. 1953. The measurement of volume changes in human limbs. J Physiol, 121:1-27.
26. Willerson JT, Ridker PM. 2004. Inflammation as a cardiovascular risk factor. Circulation, 109:112-10.
27. Wilson AM, Ryan MC, Boyle AJ. 2006. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Int J Cardiol, 106:291-7.
28. Zhang WZ, Venardos K, Chin-Dusting J, et al. 2006. Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress. Hypertension, 48:278-85.
29. Zoccali C. 2006. Asymmetric dimethylarginine ADMA.: a cardiovascular and renal risk factor on the move. J Hypertens, 24:611-9.